You have 1 action to finish to complete your account. Customize your experience by selecting your interests on the Personalization page

No matches

42 search results for: coexisting diseases

videoanimation

EoE Burden and Pathophysiology of Type 2 Inflammation

3 min

Gastroenterology

Learn about the significant burden that patients with EoE experience, and the role of type 2 inflammation in this chronic, progressive disease.

Infographic

Type 2 Inflammation Underpins Pediatric Severe Asthma

5 min

Pulmonology

Learn about the role type 2 inflammation plays in the burden and pathophysiology of severe asthma in pediatric patients.

expert video

Scientific Advances in EoE and Impact on Clinical Practice

30 min

Gastroenterology

Expert gastroenterologist Dr. Evan Dellon highlights research and scientific advances in EoE and their impact on clinical practice.

expert video

Mast Cells and the Neuroimmune Axis in CSU

10 min

Dermatology

A review of the neuroimmune mechanisms and activation of mast cells that result in itch in CSU.

expert video

Neuroimmune Axis in Atopic Dermatitis

8 min

Dermatology

A review of the neuroimmune mechanisms and changes to skin barrier that result in itch in AD.

expert video

Neuroimmune Axis and Neuroinflammation in PN

11 min

Dermatology

A review of the neuroimmune mechanisms and changes to the dermis that result in itch in PN.

expert video

Atopic Dermatitis in Children: Not Just a Skin Disease

20 min

Dermatology

In this video of the October 2024 ADVENT symposium at EAPS in Vienna, Austria, Dr Mark Boguniewicz discusses the multidimensional and cumulative disease burden of AD and its associated comorbidities in children. Dr Boguniewicz also highlights the burden experienced by caregivers of children with AD

expert video

The Potential Long-term Consequences in AD in Children: Cardiovascular Risk, Bone Health, and Mental Health

3 min

Dermatology

Dr. Marlies de Graaf highlights the potential long-term consequences of AD in children.

Podcast

ADVENT On Air | Charting a New Course: The Frontier of Early Intervention and Disease Modification in AD

23 min

Dermatology

Join Drs. April Armstrong and Lisa Beck for a conversation around the long-term burden and effects of AD. They will discuss the underlying pathophysiology of AD and how early intervention and disease modification may impact disease course.

expert video

What Went Wrong? How Dysregulated Type 2 Immunity Contributes to AD, PN, CSU, and BP

60 min

Dermatology

This full video presentation of the March 2025 ADVENT cross-dermatology symposium, hosted in Orlando, Florida features Dr. Eric Simpson, Dr. Shawn Kwatra, Dr. Jason Hawkes and Dr. Victoria Werth. The faculty present the latest information around type 2 inflammation and its association with atopic dermatitis (AD), prurigo nodularis (PN), chronic spontaneous urticaria (CSU) and bullous pemphigoid (BP).

expert video

Diagnostic Considerations: Coexistence, and Distinctions of AD & PN

3 min

Dermatology

Dr. Mark Tang talks about the coexistence of AD and PN and considerations for choosing treatment.

expert video

The Relationship Between Skin Barrier Dysfunction and Increased Risk of Allergen Sensitization in AD

3 min

Dermatology

Dr. Stephan Weidinger describes the relationship between skin barrier dysfunction and increased risk of allergen sensitization in AD.

ADVENT is a global medical education non-promotional program by Sanofi and Regeneron. This website is intended only for duly authenticated healthcare professionals in Algeria, Argentina, Australia, Austria, Bahrain, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, India, Israel, Italy, Japan, Kuwait, Latvia, Lebanon, Lithuania, Macau, Malaysia, Norway, Oman, Panama, Peru, Poland, Portugal, Qatar, Romania, Saudi Arabia, Singapore, Slovenia, South Africa, South Korea, Spain, Sudan, Sweden, Switzerland, Taiwan, Thailand, The Netherlands, Turkey, United Arab Emirates, or the United States of America.

For healthcare professionals in Algeria: Please read the additional Terms of Use.

Sanofi and Regeneron are global leaders in pharmaceutical development, each with a long history of supporting frontline physicians to improve human health and reduce the burden of disease. Driven by the same commitment to patients and their families, Sanofi and Regeneron have partnered to take on type 2 inflammation and the range of chronic conditions in which excessive inflammation plays a role.

Country/region: ItalyChange country/region